OOIR: Observatory of International Research

Papers

(The TQCC of Xenobiotica is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Mechanism-based inactivation of cytochrome P450 3A by evodol	25
Intracellular activation of 4-hydroxycyclophosphamide into a DNA-alkylating agent in human leucocytes	16
Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies	15
Oxidative metabolism of razuprotafib (AKB-9778), a sulfamic acid phosphatase inhibitor, in human microsomes and recombinant human CYP2C8 enzyme	15
Nrf2 signaling pathway studies in Drosophila melanogaster : parallel roles in human health and insect environmental responses	15
Effects of CYP3A5 polymorphism and renal impairment on the drug interaction between venetoclax and fluconazole in acute myeloid leukaemia patients	12
Inorganic mercury pharmacokinetics in man: a hybrid model	12
In vitro and in vivo metabolic profiling of PD105, a PI3Kδ inhibitor, using UHPLC-Q-Exactive plus-MS	11
Optimising pirfenidone dosage regimens in idiopathic pulmonary fibrosis: towards a guide for personalised treatment	11
Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2	9
Identification of in vivo metabolites of a potential anti-rheumatoid arthritis compound, the quinazolinone derivative PD110, using ultra-high performance liquid chromatography coupled with Q-Exactive	9
Meeting report of the second European biotransformation workshop	9
Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer	8
Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations	8
A general perspective for the conduct of radiolabelled distribution, metabolism, and excretion studies for antibody-drug conjugates	8
Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of ABCB1 3435C>T and ABCB1 2677G>T/A	7
Meeting report: DMPK optimisation strategies and quantitative translational PKPD frameworks to predict human PK and efficacious dose of targeted protein degraders	7
Toxicokinetic and mass balance of morpholine in rats	7
Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa	7
Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration	7
Meeting report: oligonucleotide ADME workshop	7
Evaluation of species differences in the metabolism of the selective Na_V1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase	7
In vivo-in vitrocorrelation of antitumor activity of heat shock protein 90 (HSP90) inhibitors with a pharmacokinetics/pharmacodynamics analysis using NCI-N87 xenograft mice	7
Human keratinocyte response to 4,4’-methylene diphenyl diisocyanate-glutathione conjugate exposure	7
Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury	6

A systematic review of allometric scaling exponents for IgG mAbs	6
Changes in the expression of drug-metabolising enzymes and drug transporters in mice with collagen antibody-induced arthritis	6
One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development	6
Roles of cytochrome P450 2A6 in the oxidation of flavone, 4′-hydroxyflavone, and 4′-, 3′-, and 2′-methoxyflavones by human liver microsomes	6
Anastrozole and related glucuronic acid conjugate are electrophilic species	6
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [ ¹⁴ C]aficamten following single oral dose administration to rats	6
Metabolism, pharmacokinetics and excretion of [¹⁴C]dimethyl fumarate in healthy volunteers: an example of xenobiotic biotransformation following endogenous metabolic pathways	6
Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans	6
Pomegranate peel polyphenols interaction with intestinal flora and its metabolic transformation	6
Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model	6
Pharmacokinetics, distribution and efficacy of triptolide PLGA microspheres after intra-articular injection in a rat rheumatoid arthritis model	6
A comprehensive analysis of six forms of cytochrome P450 2C (CYP2C) in pigs	6
Sex differences in the pharmacokinetics and tissue residues of Macleaya cordata extracts in rats	6
Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study	6
Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent d	5
The common indoor air pollutant α-pinene is metabolised to a genotoxic metabolite α-pinene oxide	5
Developmental stage and infection status may affect drug distribution in the prostate of rats	5
In vitro hepatic metabolism of the natural product quebecol	5
A cysteine trapping assay for risk assessment of reactive acyl CoA metabolites	5
Evaluation of the effect of Bovis Calculus Artifactus on eight rat liver cytochrome P450 isozymes using LC-MS/MS and cocktail approach	5
Use of stable isotope labeled (SIL) antibodies in cassette dosing to improve pharmacokinetics screening efficiency of ADCs with novel cytotoxic payloads	5
A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist	5
Absorption, distribution, metabolism and excretion of ¹⁴C-Emvododstat following a single oral dose in rats and dogs	5
In silico models to predict tubular secretion or reabsorption clearance pathway using physicochemical properties and structural characteristics	5
A physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the insecticide dimethoate	5
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor	5
Vaginal administration of 17-alpha hydroxyprogesterone caproate appears to be safe in non-pregnant female rats and rabbits	5
Curcumin and quercetin modify warfarin-induced regulation of porcine CYP1A2 and CYP3A expression and activity in vitro	5
Metabolic profiling in liver microsomes and mice of E28, a potent FLT3 inhibitor	5
Assessment of P-glycoprotein function using canine intestinal organoid-derived epithelial interfaces	5
Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children	4
Hypothesis of using albumin to improve drug efficacy in cancers accompanied by hypoalbuminemia	4
Absorption, metabolism, and excretion of [¹⁴C]-sebetralstat (KVD900) following a single oral dose in healthy male participants	4
Rutaecarpine enhances the anti-diabetic activity and hepatic distribution of metformin via up-regulation of Oct1 in diabetic rats	4
Academic foreign compound metabolism – ‘ quo vadis ’?	4
How predictive are isolated perfused liver data of in vivo hepatic clearance? A meta-analysis of isolated perfused rat liver data	4
Hepatotoxic effect of tramadol and O-desmethyltramadol in HepG2 cells and potential role of PI3K/AKT/mTOR	4
Metabolism of the antipsychotic drug olanzapine by CYP3A43	4
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 1 and 2 (rs4244285, 681G>A) alleles in vitro	4
Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver	4
Effects of paeoniflorin on the activities and mRNA expression of rat CYP1A2, CYP2C11 and CYP3A1 enzymes in vivo	4
Preparation, characterisation, pharmacokinetics and distribution of esculin microspheres administered via intravitreal injection into rabbit brain	4
Curcumin-loaded hydroxypropyl-β-cyclodextrin inclusion complex with enhanced dissolution and oral bioavailability for epilepsy treatment	4
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor	4
Through a computer monitor darkly: artificial intelligence in absorption, distribution, metabolism and excretion science	4
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)	4
Comparison between lab variability andin silicoprediction errors for the unbound fraction of drugs in human plasma	4
Clinical pharmacokinetics of cefixime: a systematic review	4
Evaluation of MTBH, a novel hesperetin derivative, on the activity of hepatic cytochrome P450 isoform in vitro and in vivo using a cocktail method by HPLC-MS/MS	4
Thank you to reviewers	4

Prospective prediction of plasma pharmacokinetics of a novel immune-modulating agent in cancer patients after intra-tumoral administration: translation from non-clinical species to humans	4
Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor	4
Pharmacokinetics, tissue distribution, plasma protein binding rate and excretion of sinoacutine following intravenous administration in female and male Sprague-Dawley rats	4
Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver	4
In vitro inhibition and induction of human liver cytochrome P450 enzymes by a novel anti-fibrotic drug fluorofenidone	4
Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning	4
Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats	4
Effects of benzophenone-3 on the liver and thyroid of adult zebrafish	4
Influence of vitamin D treatment on functional expression of drug disposition pathways in human kidney proximal tubule cells during simulated uremia	4
Role of amino acids at positions 34, 296, and 486 of cytochrome P450 2D6 in the stimulatory and inhibitory effects of psychotropic agents on dopamine formation from p-tyramine	4
Species differences in oxidative metabolism of regorafenib	4
Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes	3
Metabolite characterisation of the peptide–drug conjugate LN005 in liver S9s by UHPLC-Orbitrap-HRMS	3
Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy	3
Metabolic activation of zolmitriptan mediated by CYP2D6	3
Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats	3
Pharmacokinetics, tissue distribution and excretion of five rhubarb anthraquinones in rats after oral administration of effective fraction of anthraquinones from rheum officinale	3
Prediction of human serum concentration–time profiles of therapeutic monoclonal antibodies using common marmosets ( Callithrix jacchus ): initial assessment with canakin	3
Phenolic benzotriazoles: a class comparison of toxicokinetics of ultraviolet-light absorbers in male rats	3
Metabolic map of the antiviral drug podophyllotoxin provides insights into hepatotoxicity	3
Teratogenicity is more likely a function of primary and secondary pharmacology than caused by chemically reactive metabolites: a critical evaluation of 40 years of scientific research	3
Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients	3
Effect of formulation and route of administration on the distribution of 17-hydroxyprogesterone caproate in rats	3
Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity	3
Bioanalytical approaches to support the development of antibody-oligonucleotide conjugate (AOC) therapeutic proteins	3
Elucidating the structure and cytochrome P450-mediated mechanism for novel metabolites of GDC-0575 in rats	3
Response to the comments raised by Fernando Tricta	3
Comparisons between human and rodent hepatic glutathione S-Transferase activities reveal sex and species differences	3
Herb–drug interaction: pharmacokinetics and pharmacodynamics of anti-hypertensive drug amlodipine besylate in presence of Lepidium sativum and Curcuma longa	3
Improved preclinical drug metabolism and pharmacokinetics of pibothiadine (HEC121210), a novel hepatitis B virus capsid assembly modulator	3
Quantitative prediction of OATP1B-mediated drug–drug interactions using endogenous biomarker coproporphyrin I	3
Validation of population pharmacokinetic models: a comparison of internal and external validation approaches for hydrochlorothiazide	3
Diurnal hepatic CYP3A11 contributes to chronotoxicity of the pyrrolizidine alkaloid retrorsine in mice	3
In vitro ADME, mouse pharmacokinetics of LD14b, and bioanalysis of a novel aβ 17β-HSD10 modulator for the treatment of Alzheimer’s disease	3
Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations	3
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)	3
Metabolic exhaustion and casein kinase 1α drive deguelin-induced premature red blood cell death	3
Pharmacokinetics and metabolism of mirogabalin, a novel α₂δ ligand, in rats and monkeys	3
Chronic Toxoplasma infection affects gene expression of drug-metabolizing enzymes in mouse liver	3